Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...